Biosimilar pegfilgrastim may offer affordable treatment options for patients in France: A budget impact analysis on the basis of clinical trial and real-world data

CONCLUSIONS: The introduction of a new pegfilgrastim biosimilar (NYVEPRIA®) is potentially associated with substantial cost savings for French healthcare system.PMID:33904357 | DOI:10.1080/13696998.2021.1922252

Source: Journal of Medical Economics - April 27, 2021 Category: Health Management Authors: Jingyan Yang Rongzhe Liu Anna Granghaud Omer Zaidi Jennifer Stephens Source Type: research